Women’s Healthcare company TherapeuticsMD has announced that the Centers for Medicare and Medicaid Services (CMS) confirmed its preliminary recommendation to assign a permanent product-specific Healthcare Common Procedure Coding System (HCPCS) J Code for ANNOVERA.
According to TherapeuticsMD, ANNOVERA (segesterone acetate and ethinyl estradiol vaginal system) is the first and only FDA-approved long-lasting, reversible contraceptive for women of reproductive age that is patient-controlled and procedure-free. It is inserted for 21 continuous days and removed for 7 days each cycle for one year. ANNOVERA was developed by the global non-profit research organization, Population Council, and has been licensed to TherapeuticsMD for the U.S. market.
This new J Code will allow dispensing Public Health facilities the opportunity to gain reimbursement for ANNOVERA, including the approximately 4,900 Title X Family Planning clinics. Public Health claims submission and payment are standardized with a J Code, facilitating and streamlining billing and reimbursement. Public Health insured patients represent a growing segment of the ANNOVERA user base.
“Having a permanent J Code will simplify Public Health billing and payment, further enhancing patient access to ANNOVERA in a growing segment of our user base. This code is separate and unique to ANNOVERA as the only yearly patient controlled and procedure free vaginal system in the marketplace,” stated Hugh O’Dowd, President of TherapeuticsMD.
